PROVIDING ANSWERS WITH COMPREHENSIVE
GENE SEQUENCE ANALYSIS

Ambry Genetics is a worldwide leader in specialized genetic testing. The Company’s advancements in Cystic Fibrosis, chronic and hereditary pancreatitis, alpha-1-antitrypsin deficiency, and other severe pulmonary diseases are providing precise, cost-effective methods to aid in disease definition and early, more accurate diagnosis.  

The proprietary Ambry Test™ combines scanning and sequencing technologies to analyze a gene’s entire coding region plus surrounding critical introns. Capable of identifying approximately 99% of all disease-causing mutations of the CFTR gene, the company’s reputable Cystic Fibrosis test has an unrivaled detection rate across all ethnic groups. The Company also created the world’s first and only comprehensive genetic test for three principal genes (PRSS1, SPINK1 and CFTR) associated with Chronic and Hereditary Pancreatitis. Ambry Genetics’ most recent developments focus on diagnosis of pulmonary conditions, including Alpha-1-Antitrypsin Deficiency, Surfactant Protein B Deficiency, and Surfactant Protein C Deficiency, which is associated with pulmonary fibrosis and other interstitial lung diseases.

2000

The proprietary Ambry Test™ combines scanning and sequencing technologies to analyze a gene’s entire coding region plus surrounding critical introns.

Ambry Genetics Corp. is a privately held company.

Ambry Genetics
100 Columbia #200
Aliso Viejo, CA 92656

Ambry Genetics Fact Sheet
    (Abobe PDF document)